首页> 外文期刊>Disease models & mechanisms: DMM >Histone lysine crotonylation during acute kidney injury in mice
【24h】

Histone lysine crotonylation during acute kidney injury in mice

机译:在小鼠急性肾损伤期间的组蛋白赖氨酸克拉托蛋白化

获取原文
           

摘要

Acute kidney injury (AKI) is a potentially lethal condition for which no therapy is available beyond replacement of renal function. Post-translational histone modifications modulate gene expression and kidney injury. Histone crotonylation is a recently described post-translational modification. We hypothesized that histone crotonylation might modulate kidney injury. Histone crotonylation was studied in cultured murine proximal tubular cells and in kidneys from mice with AKI induced by folic acid or cisplatin. Histone lysine crotonylation was observed in tubular cells from healthy murine and human kidney tissue. Kidney tissue histone crotonylation increased during AKI. This was reproduced by exposure to the protein TWEAK in cultured tubular cells. Specifically, ChIP-seq revealed enrichment of histone crotonylation at the genes encoding the mitochondrial biogenesis regulator PGC-1α and the sirtuin-3 decrotonylase in both TWEAK-stimulated tubular cells and in AKI kidney tissue. To assess the role of crotonylation in kidney injury, crotonate was used to increase histone crotonylation in cultured tubular cells or in the kidneys in vivo. Crotonate increased the expression of PGC-1α and sirtuin-3, and decreased CCL2 expression in cultured tubular cells and healthy kidneys. Systemic crotonate administration protected from experimental AKI, preventing the decrease in renal function and in kidney PGC-1α and sirtuin-3 levels as well as the increase in CCL2 expression. For the first time, we have identified factors such as cell stress and crotonate availability that increase histone crotonylation in vivo. Overall, increasing histone crotonylation might have a beneficial effect on AKI. This is the first observation of the in vivo potential of the therapeutic manipulation of histone crotonylation in a disease state.
机译:急性肾损伤(AKI)是一种潜在的致命条件,无需替代肾功能即可提供疗法。翻译后组蛋白修饰调节基因表达和肾损伤。组蛋白克拉托甲基化是最近描述的翻译后修饰。我们假设组蛋白曲丁基化可能调节肾损伤。在培养的鼠近端管状细胞中以及由叶酸或顺铂诱导的αKi的小鼠中研究组蛋白曲丁基化。在来自健康小鼠和人肾组织的管状细胞中观察组蛋白赖氨酸克拉蛋白。肾组织组蛋白克拉托蛋白在AKI期间增加。这是通过暴露于培养的管状细胞中的蛋白质调节来繁殖。具体而言,芯片SEQ在编码线粒体生物发生调节剂PGC-1α和SIRTUIN-3在调节的管状细胞和Aki肾组织中的SIRTUIN-3分子酶中的基因中揭示了组蛋白喋喋不克酶的富集。为了评估克拉托蛋白在肾损伤中的作用,配体用于增加培养的管状细胞或体内肾脏中的组蛋白喋喋不克。 rotonate增加了PGC-1α和Sirtuin-3的表达,并降低了培养的管状细胞和健康肾脏中的CCl2表达。从实验性aki保护的全身静脉醛施防,防止肾功能和肾脏功能的降低和肾PGC-1α和Sirtuin-3水平以及CCl2表达的增加。我们首次鉴定了细胞应激和relotonate可用性等因素,这些可用性增加了体内组蛋白克拉托蛋白化。总体而言,增加组蛋白克拉托蛋白可能对AKI具有有益的影响。这是在疾病状态下首次观察组蛋白克拉蛋白治疗的体内潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号